Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1989-11-13
pubmed:abstractText
Intravenous teicoplanin has been used to treat 23 cases of gram-positive-bacterial endocarditis, usually with 3 to 7 mg/kg every 12 h on the first day, followed by 3 to 7 mg/kg every 24 h. For some cases (staphylococcal and enterococcal endocarditis), the dosage was 8 to 14.4 mg/kg per day and/or other antibiotics were given. The mean duration was 48.2 days (range, 23 to 130 days). Of 23 patients, 21 (91.3%) had negative cultures or were cured. A total of 18 patients were treated with teicoplanin alone; of these, 4 had surgery, and all (except 2 who relapsed) were cured. Teicoplanin was combined with one or more antibiotics in five cases; in all cases appropriate cultures were negative, but three patients died during therapy or follow-up. Mild renal impairment was seen in two patients; both were receiving teicoplanin in combination with an aminoglycoside. We conclude that intravenous teicoplanin administered once a day at doses of 7 to 14 mg/kg per day is well tolerated, easy to administer, and may represent an efficacious therapy for gram-positive-bacterial endocarditis.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2871102, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2940303, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2942100, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2949024, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2960643, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-2962071, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-3157344, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-3881943, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-3925771, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-3946140, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-4014278, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-4578469, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6213192, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-622043, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6221692, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6227280, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6227282, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6236747, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-6240962, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-7011141, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-7446550, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-832352, http://linkedlifedata.com/resource/pubmed/commentcorrection/2529815-921443
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1329-34
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
pubmed:affiliation
Cattedra di Ematologia, Dipartimento di Biopatologia Umana, Rome, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial